[go: up one dir, main page]

ATE277038T1 - Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung - Google Patents

Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung

Info

Publication number
ATE277038T1
ATE277038T1 AT98962567T AT98962567T ATE277038T1 AT E277038 T1 ATE277038 T1 AT E277038T1 AT 98962567 T AT98962567 T AT 98962567T AT 98962567 T AT98962567 T AT 98962567T AT E277038 T1 ATE277038 T1 AT E277038T1
Authority
AT
Austria
Prior art keywords
chelating agents
oxide releasing
nitrogen oxide
therapeutic use
nitric oxide
Prior art date
Application number
AT98962567T
Other languages
English (en)
Inventor
Robertson Towart
Jan Olof Gustav Karlsson
Lars Goeran Wistrand
H Kan Malmgren
Original Assignee
Amersham Health As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9727226.4A external-priority patent/GB9727226D0/en
Priority claimed from GBGB9805450.5A external-priority patent/GB9805450D0/en
Application filed by Amersham Health As filed Critical Amersham Health As
Application granted granted Critical
Publication of ATE277038T1 publication Critical patent/ATE277038T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
AT98962567T 1997-12-23 1998-12-18 Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung ATE277038T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9727226.4A GB9727226D0 (en) 1997-12-23 1997-12-23 Method
GBGB9805450.5A GB9805450D0 (en) 1998-03-13 1998-03-13 Method
PCT/GB1998/003840 WO1999033823A1 (en) 1997-12-23 1998-12-18 Nitric oxide releasing chelating agents and their therapeutic use

Publications (1)

Publication Number Publication Date
ATE277038T1 true ATE277038T1 (de) 2004-10-15

Family

ID=26312841

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98962567T ATE277038T1 (de) 1997-12-23 1998-12-18 Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung

Country Status (7)

Country Link
US (1) US6391895B1 (de)
EP (1) EP1060174B1 (de)
JP (1) JP2001527072A (de)
AT (1) ATE277038T1 (de)
AU (1) AU1770299A (de)
DE (1) DE69826528T2 (de)
WO (1) WO1999033823A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367002A1 (en) 1999-03-19 2000-09-28 Michael A. Moskowitz Increasing cerebral bioavailability of drugs
US20030186948A1 (en) * 2000-03-21 2003-10-02 Jeffrey Kudlow O-linked N-acetylglucosamine pathway in the pathogenesis of neurodegeneration and diabetes
WO2001070236A1 (en) * 2000-03-21 2001-09-27 Uab Research Foundation Preventing and/or treating diabetes mellitus
US6946484B2 (en) 2000-04-26 2005-09-20 Cellegy Pharmaceuticals, Inc. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
JP2005501060A (ja) * 2001-08-10 2005-01-13 ニトロメッド，インク． 硫黄含有有機硝酸化合物の使用法
US6679827B2 (en) 2001-10-11 2004-01-20 Robert E. Sandstrom Magnetic field enhancement of tumor treatment
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
US6627602B2 (en) 2001-11-13 2003-09-30 Duke University Preventing desensitization of receptors
WO2003090782A1 (en) 2002-04-26 2003-11-06 Takeda Chemical Industries, Ltd. Cell death inhibitor
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US20020168424A1 (en) * 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
MXPA05004290A (es) * 2002-10-24 2005-11-23 Enos Pharmaceuticals Inc Formulaciones de l-arginina de liberacion sostenida, y metodos para su fabricacion y uso.
CA2537222A1 (en) 2003-07-09 2005-01-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US7041286B2 (en) * 2003-07-23 2006-05-09 Nerenberg Arnold P Composition for mitigating a pernicious thrombotic event
AU2004279298B2 (en) * 2003-09-29 2009-01-29 Palmetto Pharmaceuticals, Llc Sustained release L-arginine formulations and methods of manufacture and use
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
EP1718603A4 (de) 2004-02-09 2009-09-23 Noxilizer Inc Stickstoffmonoxid freisetzende moleküle
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20070148154A1 (en) * 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
WO2006125123A2 (en) * 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
JP5274248B2 (ja) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子
AU2008339091B2 (en) 2007-12-14 2014-08-07 Egetis Therapeutics Ab Compounds for use in the treatment of cancer
EP2237788A4 (de) * 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc Aerosolisierte nitrit- und stickoxidspendende verbindungen und ihre verwendung
WO2009137071A1 (en) * 2008-05-09 2009-11-12 Duke University Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells
US8207208B2 (en) * 2008-05-15 2012-06-26 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
JP5868852B2 (ja) 2009-07-06 2016-02-24 プレッドファルマ・アーベー マンガン錯体化合物と非マンガン錯体形態の同化合物の組み合わせを用いる医薬組成物及び治療方法
ES2958410T3 (es) 2009-08-21 2024-02-08 Novan Inc Geles tópicos
DK2467173T3 (da) 2009-08-21 2019-07-29 Novan Inc Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
WO2011050319A2 (en) * 2009-10-23 2011-04-28 Oregon Health & Science University Inhibiting the deleterious effect of anthracyclines
AU2010328230B2 (en) 2009-12-07 2016-06-02 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
DE102010047283B4 (de) 2010-10-01 2012-03-22 Heinz Kiefer Untersuchungsverfahren/Screeningverfahren unter Einbeziehung von lebenden Geweben des Blutgefäß-Systems
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
MX2014008247A (es) 2012-01-05 2015-03-09 Pledpharma Ab Calmangafodipir, una nueva entidad quimica, y otros complejos de metal mezclados, metodos de preparacion, composiciones y metodos de tratamiento.
EP3421042B1 (de) 2012-03-07 2024-04-17 Beyond Air Ltd Inhalation von stickoxid zur behandlung von atemwegserkrankungen
BR112015009963A2 (pt) 2012-11-02 2017-07-11 Pledpharma Ab uso de compostos para a preparação de composições farmacêuticas para o tratamento de câncer
KR101555523B1 (ko) * 2014-02-28 2015-09-25 부산대학교 산학협력단 산화질소 방출성 상처치료 필름 및 이의 제조방법
EP3538155B1 (de) * 2016-11-14 2020-09-16 Karlsson-Tuner Invest AS Verwendung von koordinierten dipyridoxylverbindungen mit nicht-übergangsmetallen zur vorbeugung und behandlung von chemotherapieinduzierter psn
EP4093205A4 (de) * 2020-02-07 2024-02-21 KNOW Bio, LLC Stickoxidfreisetzende antibakterielle verbindungen, formulierungen und zugehörige verfahren
KR102462782B1 (ko) * 2021-01-29 2022-11-03 포항공과대학교 산학협력단 환원반응성 일산화질소 공여 화합물 및 전달체 시스템
US20240325334A1 (en) * 2021-09-13 2024-10-03 Seoul National University R&Db Foundation Composition for generating nitrogen monoxide

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3129906C3 (de) * 1981-07-24 1996-12-19 Schering Ag Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
US4687659A (en) * 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
AR246956A1 (es) * 1987-05-08 1994-10-31 Salutar Inc Compuesto quelante, un intermediario para preparar el mismo, y un procedimiento para preparar una composicion de medio de contraste.
US5198208A (en) * 1987-07-16 1993-03-30 Nycomed Imaging As Aminopolycarboxylic acids and derivatives thereof
WO1990003804A1 (en) * 1988-09-27 1990-04-19 Salutar, Inc. Chelate compositions
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
AU3969793A (en) * 1992-04-13 1993-11-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of nitric oxide/nucleophile complexes for the treatment of cancer
EP0726768B1 (de) * 1993-11-02 2000-05-17 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, Department of Health and Human Services Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden
AU5527196A (en) * 1995-04-04 1996-10-23 Brigham And Women's Hospital Inhibiting retroviral replication
WO1996039409A1 (en) * 1995-06-05 1996-12-12 Nitromed, Inc. Nitrosylated and nitrated superoxide oxidants and reductants
GB9613182D0 (en) * 1996-06-24 1996-08-28 Nycomed Imaging As Method
US20030165985A1 (en) 2001-05-08 2003-09-04 Derry Jonathan M.J. Methods for identifying compounds that antagonize cd40 signaling

Also Published As

Publication number Publication date
US6391895B1 (en) 2002-05-21
AU1770299A (en) 1999-07-19
DE69826528D1 (de) 2004-10-28
EP1060174B1 (de) 2004-09-22
WO1999033823A1 (en) 1999-07-08
JP2001527072A (ja) 2001-12-25
EP1060174A1 (de) 2000-12-20
DE69826528T2 (de) 2006-02-23

Similar Documents

Publication Publication Date Title
ATE277038T1 (de) Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung
DE69716104D1 (de) Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände
BR9811946A (pt) Método para prevenção ou tratamento de distúrbios e doenças dependentes de estrogênio
DK1039887T3 (da) Anvendelse af aminothiolforbindelser til behandling af neuro- og nefrolidelser og terapeutiske toksiciteter
YU77000A (sh) Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c
DE69033299D1 (de) Verwendung von Carnosolsäure wegen seiner anticarcinogenen und antiviralen Eigenschaften
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
IL140159A0 (en) Neuroprotective composition for the prevention and/or treatment of nervous and behavioral alterations due to anxiety states or depression
ITFI980208A0 (it) Derivati anticolinesterasici per il trattamento delle sindromi dolorose funzionali e/o organiche
EP0506658A4 (en) Compositions and method for treating painful, inflammatory or allergic disorders
ATE121727T1 (de) Chelatbildner, die eine ortho-bindende funktionelle gruppe besitzen und komplexe davon.
ATE338553T1 (de) Antitumorkombination aus 3-amino-1,2,4- benzotriazine 1,4-dioxid/paclitaxel/platin
GB9309387D0 (en) Nitric oxide scavengers
FR2825273B1 (fr) Composition pour le traitement des signes cutanes du vieillissement
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
EP1038524A4 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
WO2001030334A3 (en) 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation
EP0757697A4 (de) Verwendung von agentien, die die interzellülare wechselwirkung inhibieren, in der behandlung von viralen infektionen des atemweges
GB9916882D0 (en) Antitumor synergistic composition
KR960016353U (ko) 형태와 기능이 경혈치료용으로 재구성된 파스

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties